@zhangh73
Hello! Yes, I have read a lot of the literature too and have seen that as well! I agree - it is a pretty rare mutation, and even then there are additional characteristics that are required to be beneficial. The higher the tumor mutation burden, apparently the better. I believe ultra high was defined as greater than 100 mutations, and mine was greater than 350 mutations. The biggest factor in going forward with radiation for me was that this is still the recommended standard of care at the moment. In the paperwork associated with the clinical trial, under potential risks, cancer recurrence was listed as number one. But I do really believe the time is coming when the standard of care will change to exclude additional treatment.